New innovative therapies for benign prostatic hyperplasia any advance?

Current Opinion in Urology

Volumn 13, Issue 1, 2003, Pages 11-15

  Klingler, H Christoph ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

blockers; Benign prostatic hyperplasia; Growth factors; Laser therapy; Lower urinary tract symptoms

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; FINASTERIDE; HERBACEOUS AGENT; PLACEBO; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

APOPTOSIS; BLADDER OBSTRUCTION; CELL PROLIFERATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; EVALUATION; GENE OVEREXPRESSION; HERBAL MEDICINE; HUMAN; MEDICAL LITERATURE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PUBLICATION; REVIEW; SURVIVAL TIME; SYMPTOMATOLOGY; TRANSURETHRAL RESECTION; TREATMENT FAILURE; URINARY TRACT DISEASE; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BIOPSY, NEEDLE; CONTROLLED CLINICAL TRIALS; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; PHYTOTHERAPY; PROGNOSIS; PROSTATIC HYPERPLASIA; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME;

EID: 0037238213     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200301000-00003     Document Type: Review

References (30)

1. Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the normative ageing study. Am J Epidemiol 1985; 125:78-82.
2. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate 1990; 3 (Suppl):1-7.
3. Klingler HC, Bretland AJ, Reid SV, et al. Regulation of connective tissue stroma in the prostate by transforming growth factor beta TGFβ. Prostate 1999; 41:110-120.
4. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002; 19:413-425.
5. Wise GJ, Md EO. Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons. Curr Urol Rep 2001; 2:285-291.
6. Haggstrom S, Torring N, Moller K, et al. Effects of finasteride on vascular endothelial growth factor. Scand J Urol Nephrol 2002; 36:182-187.
7. Jakowlew SB, Moody TW, Mariano JM. Transforming growth factor beta receptors in human cancer cell lines: analysis of transcript, protein and proliferation. Anticancer Res 1997; 17:1849-1860.
8. Torring N, Moller-Ernst Jensen K, Lund L, et al. Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo-controlled randomized study. BJU Int 2002; 89:583-590.
9. Kramer G, Steiner GE, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52:43-58.
10. Handisurya A, Steiner GE, Stix U, et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate 2001; 49:251-262.
11. Gerber GS. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep 2002; 3:285-291.
12. Fagelman E, Lowe FC. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin North Am 2002; 29:23-29.
13. Dvorkin L, Song KY. Herbs for benign prostatic hyperplasia. Ann Pharmacother 2002; 36:1443-1452.
14. Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002; 19:390-396.
15. Erdogru T, Gulkesen KH, Kukul E, et al. Increased bladder apoptosis with alpha-1 adrenoceptor antagonists in benign prostatic hyperplasia. Scand J Urol Nephrol 2002; 36:188-193.
16. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002; 41:497-506; discussion 506-507.
17. de la Rosette JJ, Kortmann BB, Rossi C, et al. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002; 167:1734-1739.
18. Tanaka Y, Masumori N, Itoh N, et al. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. J Urol 2002; 167:2492-2495.
19. Mimata H, Satoh F, Ohno H, et al. Clinical characteristics of alpha-blocker responders in men with benign prostatic hyperplasia. Urol Int 2002; 68:237-242.
20. Tan AH, Gilling PJ. Holmium laser prostatectomy: current techniques. Urology 2002; 60:152-156.
21. Muschter R, Gilling AP. Lasers for median lobe hyperplasia. Curr Urol Rep 2001; 2:306-310.
22. Das A, Kennett K, Fraundorfer M, Gilling P. Holmium laser resection of the prostate (HoLRP): 2-year follow-up data. Tech Urol 2001; 7:252-255.
23. Fraundorfer MR, Gilling PJ, Kennett KM, Dunton NG. Holmium laser resection of the prostate is more cost effective than transurethral resection of the prostate: results of a randomized prospective study. Urology 2001; 57:454-458.
24. Van Melick HH, Van Venrooij GE, Eckhardt MD, Boon TA. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: urodynamic effects. J Urol 2002; 168:1058-1062.
25. Shingleton WB, Farabaugh P, May W. Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia. Urology 2002; 60:305-308.
26. Thalmann GN, Mattei A, Treuthardt C, et al. Transurethral microwave therapy in 200 patients with a minimum follow-up of 2 years: urodynamic and clinical results. J Urol 2002; 167:2496-2501.
27. Wagrell L, Schelin S, Nordling J, et al. Feedback microwave thermotherapy versus TURP for clinical BPH: a randomized controlled multicenter study. Urology 2002; 60:292-299.
28. Norby B, Nielsen HV, Frimodt-Moller PC. Cost-effectiveness of new treatments for benign prostatic hyperplasia: results of a randomized trial comparing the short-term cost-effectiveness of transurethral interstitial laser coagulation of the prostate, transurethral microwave thermotherapy and standard transurethral resection or incision of the prostate. Scand J Urol Nephrol 2002; 36:286-295.
29. Eaton AC, Francis RN. The provision of transurethral prostatectomy on a daycase basis using bipolar plasma kinetic technology. BJU Int 2002; 89:534-537.
30. Ditrolio J, Patel P, Watson RA, Irwin RJ. Chemo-ablation of the prostate with dehydrated alcohol for the treatment of prostatic obstruction. J Urol 2002; 167:2100-2103; discussion 2103-2104.